We continue the momentum for a𝓡 diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. We have been replenishing our innovation pipeline with HANSIZHUANG (serplulimab injection, anti-PD-1 mAb) as backbone.
Fully leveraging the global research and development platform, we have been exploring pipeline opp🐓ortunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-ജbased immuno-oncology combination therapies.
We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 48,000L for now with an estimate of 144,000L in 2026. Xuhui Facility and Songjiang First Plant are both certificated by China and the EU Good Man൩ufacturing Practice (GMP).
We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, 💮pricing, strategy and sales and compromising of about 450 professionals; we have also joined forces with oversea partners, expanding our reach in major ma🐼rkets as well as emerging markets worldwide.
